A5064360947- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Sarcoidosis and Beryllium Toxicity Research
- Neonatal Respiratory Health Research
- Inflammasome and immune disorders
- Tuberculosis Research and Epidemiology
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- IL-33, ST2, and ILC Pathways
- Lung Cancer Treatments and Mutations
- Inhalation and Respiratory Drug Delivery
- Lung Cancer Diagnosis and Treatment
Fraunhofer Institute for Toxicology and Experimental Medicine
2019-2023
German Center for Lung Research
2020-2022
Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. In this study, we focus on the properties of airway basal cells (ABC) obtained from patients IPF (IPF-ABC). Single cell RNA sequencing (scRNAseq) bronchial brushes revealed extensive reprogramming IPF-ABC towards KRT17 high PTEN low dedifferentiated type. 3D organoid model, compared to ABC healthy volunteers, give rise more bronchospheres, de novo structures resembling lung developmental...
Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease harboring significant morbidity and mortality despite recent advances in therapy. Regardless of severity acute exacerbations (IPF-AEs) may occur leading to considerable loss function are the cause death IPF. Histologic features IPF-AE very similar respiratory distress syndrome (ARDS), but underlying mechanisms incompletely understood. We investigated role NLRP3 inflammasome IPF IPF-AE. Bronchoalveolar lavage (BAL)...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. CC-chemokine ligand 18 (CCL18) predictive of survival in IPF. We described correlation CCL18 serum levels the genotype rs2015086 C > T polymorphism CCL18-gene, which was associated pre-antifibrotic cohort (Part-A). Herein (Part-B), we aimed to validate these findings and study effects antifibrotics. Two cohorts were prospectively recruited, cohort-A (n = 61, pre-antifibrotic) B 101, received antifibrotics)....
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. In this study we focus on the profibrotic properties of airway basal cells (ABC) obtained from patients IPF (IPF-ABC). Single cell RNA sequencing bronchial brushes revealed extensive reprogramming IPF-ABC towards KRT17 high PTEN low dedifferentiated type. 3D organoid model, compared to ABC healthy volunteers, give rise more bronchospheres, de novo structures resembling lung developmental...
<b>Background:</b> Idiopathic pulmonary fibrosis (IPF) is a progressive disease harboring significant morbidity and mortality despite recent advances in therapy. Regardless of severity acute exacerbations (IPF-AE) may occur which are the leading cause death IPF. Histologic features IPF-AE very similar to respiratory distress syndrome (ARDS) but underlying mechanisms incompletely understood. <b>Aim:</b> To investigate role NLRP3 inflammasome IPF IPF-AE. <b>Methods:</b> Alveolar macrophages...
Einführung Die Kurzzeitkultur humaner Präzisionslungenschnitte (PCLS) ist seit langem zur Medikamententestung etabliert, stößt aber nach spätestens 5 Tagen in Bezug auf die Zellvitalität an ihre Grenzen. Zur Testung der Wirksamkeit von antifibrotischen Medikamenten bedarf es einer längeren Kulturdauer Patientengewebe, um eine möglichst exakte Vorhersage Modulation Fibrosevorgängen im Patienten treffen zu können. In folgenden Studie haben wir Methode Kultivierung PCLS IPF-Lungengewebe über...
Introduction Transforming Growth Factor β (TGF-β) is considered as a key player in multiple fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF). Previous data suggested that unstimulated alveolar macrophages from IPF patients show already high levels of TGF-β signaling and inhibition can be tested on native BAL cells. Objective In this study we evaluate the effect SB-431542, an inhibitor TGFBR1 thereby signaling, transcriptome ex vivo cells 9 patients. Workflow Culture was...
IPF ist eine chronisch progressive Erkrankung mit infauster Prognose. Vor Einführung der antifibrotischen Therapie Pirfenidon und Nintedanib hatte unsere Arbeitsgruppe die prognostische Relevanz CCL18 Serumkonzentration bei unbehandelten IPF-Patienten in Bezug auf Krankheitsprogress Mortalität erstmals beschrieben. Ziel dieser Studie war es zu überprüfen, ob Serumwert auch antifibrotisch behandelten Patienten Aussagekraft hat Wert dem Genotyp korreliert.
Introduction IPF is a progressive disease with poor prognosis. Recently antifibrotic treatment either pirfenidone or nintedanib were approved. Both drugs have been shown to slow progression. In previous studies undertaken before the approval of we and others reported on predictive value serum CCL18 concentration in patients not treated antifibrotics. Objective To investigate concentrations progression mortality cohort drugs. addition, genotyped promoter polymorphism analyze correlation...
<b>Aims and objectives:</b> Single cell RNA sequencing revealed a forthcoming role of aberrantly programmed basal cells in the fibro-epithelial niche idiopathic pulmonary fibrosis (IPF). Since therapeutic effects monoclonal antibodies targeting non-junctional claudin-1 (CLDN1) were shown liver with high efficacy safety, we aimed to investigate CLDN1 signaling within epithelial-mesenchymal crosstalk IPF. <b>Methods:</b> Spatial abundance IPF lung was investigated via immunohistochemistry...